Chalons En Champagne

Researchers are evaluating a new ultrasound algorithm called EMERALD-US to improve diagnosis of acute non-traumatic dyspnea in patients aged 50 and older admitted to emergency departments. The study aims to assess how accurately this ultrasound method can identify the three main causes of dyspnea heart failure, pneumonia, and obstructive pulmonary disease exacerbation. This is a prospective multicenter study focusing on the emergency setting where rapid and accurate diagnosis is critical for patient outcomes. The ultrasound exams include lung, cardiac, and vascular scans performed within the first hour after the patients initial medical contact in the emergency department. These exams are done by physicians who are not involved in patient care and are later reviewed blindly by a centralized core laboratory. The study also compares the ultrasound diagnosis with the clinical diagnosis made by emergency physicians. Additional laboratory and radiological tests are collected to assess the algorithms diagnostic accuracy for both common and less frequent causes of dyspnea. Participants will undergo ultrasound examinations lasting up to 30 minutes, alongside routine clinical, laboratory, and imaging assessments. The main outcome measured is the final discharge diagnosis determined by a panel of three senior physicians, based on all clinical data and hospital stay lasting about two weeks. The study also monitors patient management time in the emergency department and 30-day mortality. Researchers will examine the feasibility of using the ultrasound algorithm in emergency settings and its impact on improving diagnostic accuracy and patient survival.

This research aims to describe how patients aged 18 years or older with moderate to severe atopic dermatitis AD are managed with systemic therapy. It focuses on patients eligible for or currently receiving systemic treatments, following their care under real-world conditions. The study involves French dermatologists experienced in AD management, whether practicing in hospitals or private offices. Treatment decisions are made independently by the physicians and not influenced by the study enrollment. Participants will receive systemic treatments for AD prescribed by their doctors as part of routine care, with no investigational drugs involved. Information will be collected during regular visits according to usual clinical practice. The study will follow patients for one year, tracking their treatments and management without altering standard care. During the year, patients will be assessed at baseline, 6 months, and 12 months. Researchers will collect data on previous and current treatments, treatment adherence, changes in disease severity, itch, sleep disturbance, skin pain, quality of life, psychological health, work absences, and hospitalizations related to AD. This comprehensive follow-up aims to better understand how systemic therapies are used and their impact on patients in everyday clinical settings.